Related Experiment Videos

Left ventricular diastolic function in hypertrophic cardiomyopathy

R O Bonow1

  • 1Cardiology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Herz
|February 1, 1991
PubMed

Insights

Impaired diastolic function in hypertrophic cardiomyopathy affects left ventricular filling and can cause symptoms like dyspnea. Calcium channel blockers, particularly verapamil, show promise in improving relaxation and filling dynamics.

Area of Science:

  • Cardiology
  • Cardiovascular Physiology

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by impaired left ventricular (LV) diastolic function due to hypertrophy and stiffness.
  • This dysfunction leads to altered LV filling, reduced distensibility, increased LV filling pressures, and coronary microcirculation compression.

Purpose of the Study:

  • To explore the mechanisms underlying impaired LV diastolic function in HCM.
  • To evaluate the impact of calcium channel blockers on LV diastolic function and filling in HCM patients.

Main Methods:

  • The study reviews factors affecting passive elastic properties and active relaxation of the LV in HCM.
  • It discusses inactivation-dependent and load-dependent mechanisms of impaired relaxation.
  • The effects of calcium channel blockers (verapamil, diltiazem, nifedipine) on LV function were examined.

Main Results:

  • Reduced LV distensibility contributes to symptoms such as fatigue, dyspnea, and angina.
  • Impaired relaxation involves increased intracellular calcium and prolonged contractile protein interaction, alongside potential myocardial ischemia.
  • Calcium channel blockers favorably influence LV relaxation and filling; verapamil improves stroke volume without increasing end-diastolic pressure.

Conclusions:

  • Impaired diastolic function is central to HCM pathophysiology and clinical presentation.
  • Verapamil and diltiazem are effective in improving LV diastolic function and filling patterns in HCM.
  • Targeting diastolic dysfunction with specific calcium channel blockers offers therapeutic potential for HCM patients.

Related Concept Videos